Skip to main content

Articles

Page 5 of 9

  1. PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 blockade therapy has been trialed in a b...

    Authors: Jin-Yu Sun, Dengke Zhang, Songquan Wu, Min Xu, Xiao Zhou, Xiao-Jie Lu and Jiansong Ji
    Citation: Biomarker Research 2020 8:35
  2. Early progression after the first-line R-CHOP treatment leads to a very dismal outcome and necessitates alternative treatment for patients with diffuse large B-cell lymphoma (DLBCL). This study aimed to develo...

    Authors: Jialin Ma, Zheng Yan, Jiuyang Zhang, Wenping Zhou, Zhihua Yao, Haiying Wang, Junfeng Chu, Shuna Yao, Shuang Zhao, Peipei Zhang, Yuanlin Xu, Qingxin Xia, Jie Ma, Bing Wei, Shujun Yang, Kangdong Liu…
    Citation: Biomarker Research 2020 8:33
  3. The term “pharmacogenetics” is used to describe the study of variability in drug response due to heredity. It is associated with “gene – drug interactions”. Later on, the term “pharmacogenomics” has been intro...

    Authors: Nelly N. Miteva-Marcheva, Hristo Y. Ivanov, Dimitar K. Dimitrov and Vili K. Stoyanova
    Citation: Biomarker Research 2020 8:32
  4. Acute myeloid leukemia (AML) is a malignant hematological neoplasm of myeloid progenitor cells. Mutations of FLT3 in its tyrosine kinase domain (FLT3-TKD) are found in ~ 8% of patients with AML, with D835Y as ...

    Authors: Yao Guo, Honghua Sun, Dengyang Zhang, Yuming Zhao, Mingxia Shi, Ming Yang, Shu Xing, Xueqi Fu, Ting Bin, Bo Lu, Shunjie Wu, Xiaojun Xu, Xuesong Xu, Yun Chen and Zhizhuang Joe Zhao
    Citation: Biomarker Research 2020 8:30
  5. The recently updated European LeukemiaNet risk stratification guidelines combine cytogenetic abnormalities and genetic mutations to provide the means to triage patients with acute myeloid leukemia for optimal ...

    Authors: Era L. Pogosova-Agadjanyan, Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, I-Ming L. Chen, Harry P. Erba, John E. Godwin, Isaac C. Jenkins, Min Fang, Mike Huynh, Kenneth J. Kopecky, Alan F. List, Jasmine Naru, Jerald P. Radich, Emily Stevens…
    Citation: Biomarker Research 2020 8:29
  6. Beyond hemostasis, thrombosis and wound healing, it is becoming increasingly clear that platelets play an integral role in inflammatory response and immune regulation. Platelets recognize pathogenic microorgan...

    Authors: Yufei Chen, Haoxuan Zhong, Yikai Zhao, Xinping Luo and Wen Gao
    Citation: Biomarker Research 2020 8:28
  7. The early detection of tumors upon initial diagnosis or during routine surveillance is important for improving survival outcomes. Here, we investigated the feasibility and clinical significance of circulating ...

    Authors: Qiong Li, Wei Zhang, Jiali Li, Jingkang Xiong, Jia Liu, Ting Chen, Qin Wen, Yunjing Zeng, Li Gao, Lei Gao, Cheng Zhang, Peiyan Kong, Xiangui Peng, Yao Liu, Xi Zhang and Jun Rao
    Citation: Biomarker Research 2020 8:27
  8. Alterations of genes encoding subunits of the BAF/PBAF complexes are among the most frequent gene aberrations in human cancer. Such alterations have been shown to have an impact on tumor microenvironnement and...

    Authors: Kevin Courtet, Yec’han Laizet, Carlo Lucchesi, Alban Bessede and Antoine Italiano
    Citation: Biomarker Research 2020 8:26
  9. Circular RNAs (circRNAs) are covalently linked RNAs that exhibit individual strand with a closed-loop framework compared with a conserving, steady and abundant linear counterpart. In recent years, as high-thro...

    Authors: Zhouxiao Li, Ye Cheng, Fan Wu, Liangliang Wu, Hongyong Cao, Qian Wang and Weiwei Tang
    Citation: Biomarker Research 2020 8:25
  10. Defect in DNA damage response (DDR) is a common feature of cancer cells, which regulates tumor growth and therapeutic response. Recently, the approval of immune checkpoint blockade (ICB) for tumors with defect...

    Authors: Jing Zhang, David J. H. Shih and Shiaw-Yih Lin
    Citation: Biomarker Research 2020 8:23
  11. The KRAS mutation is the second most common genetic variant in Chinese non-small cell lung cancer (NSCLC) patients. At the 2019th World Conference of Lung Cancer, the KRAS G12C-specific inhibitor AMG510 showed pr...

    Authors: Si-Yang Liu, Hao Sun, Jia-Ying Zhou, Guang-Ling Jie, Zhi Xie, Yang Shao, Xian Zhang, Jun-Yi Ye, Chun-Xiang Chen, Xu-Chao Zhang, Qing Zhou, Jin-Ji Yang and Yi-Long Wu
    Citation: Biomarker Research 2020 8:22
  12. Lysyl oxidase (LOX) has been described as necessary for premetastatic niche formation in epithelium-derived malignancies and its expression level therefore correlates with risk of metastatic disease and overal...

    Authors: Desiree Kunadt, Michael Kramer, Claudia Dill, Heidi Altmann, Lisa Wagenführ, Brigitte Mohr, Christian Thiede, Christoph Röllig, Johannes Schetelig, Martin Bornhäuser, Markus Schaich and Friedrich Stölzel
    Citation: Biomarker Research 2020 8:20
  13. Chimeric antigen receptor T cells (CAR-T cells) therapy has been well recognized for treating B cell-derived malignancy. However, the efficacy of CAR-T cells against solid tumors remains dissatisfactory, parti...

    Authors: Le Qin, Ruocong Zhao, Dongmei Chen, Xinru Wei, Qiting Wu, Youguo Long, Zhiwu Jiang, Yangqiu Li, Haipeng Wu, Xuchao Zhang, Yilong Wu, Shuzhong Cui, Wei Wei, Huihui Yao, Zixia Liu, Su Cao…
    Citation: Biomarker Research 2020 8:19
  14. Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstratin...

    Authors: Yuru Nie, Weiqing Lu, Daiyu Chen, Huilin Tu, Zhenling Guo, Xuan Zhou, Meifang Li, Sanfang Tu and Yuhua Li
    Citation: Biomarker Research 2020 8:18
  15. Acute myeloid leukemia (AML) is a clonal malignancy characterized by genetic heterogeneity due to recurrent gene mutations. Treatment with cytotoxic chemotherapy has been the standard of care for more than hal...

    Authors: Jifeng Yu, Peter Y. Z. Jiang, Hao Sun, Xia Zhang, Zhongxing Jiang, Yingmei Li and Yongping Song
    Citation: Biomarker Research 2020 8:17
  16. For the detection of malignant mesothelioma additional markers are needed besides the established panel consisting of calretinin and mesothelin. The aim of this study was the identification and verification of...

    Authors: Daniel G. Weber, Swaantje Casjens, Alexander Brik, Irina Raiko, Martin Lehnert, Dirk Taeger, Jan Gleichenhagen, Jens Kollmeier, Torsten T. Bauer, Thomas Brüning and Georg Johnen
    Citation: Biomarker Research 2020 8:15
  17. Treatment with chimeric antigen receptor (CAR)-engineered T cells directed against the B-cell maturation antigen (BCMA) promoted transient recovery from multiple myeloma (MM). However, the absence of this anti...

    Authors: Liqing Kang, Jian Zhang, Minghao Li, Nan Xu, Wei Qi, Jingwen Tan, Xiaoyan Lou, Zhou Yu, Juanjuan Sun, Zhenkun Wang, Chengcheng Fu, Xiaowen Tang, Haiping Dai, Jia Chen, Depei Wu and Lei Yu
    Citation: Biomarker Research 2020 8:14
  18. Extramedullary relapse is an important cause of treatment failure among patients with acute lymphoblastic leukemia (ALL). This type of relapse is commonly observed in the central nervous system, while it is ra...

    Authors: Ze-Fa Liu, Li-Yun Chen, Jin Wang, Li-qing Kang, Hua Tang, Yao Zhou, Hai-Xia Zhou, Ai-Ning Sun, De-Pei Wu and Sheng-Li Xue
    Citation: Biomarker Research 2020 8:12
  19. The poor response to current PD-1/PD-L1 inhibitors in lung cancer patients requires development of novel immunotargets. Immunoglobulin-like transcript (ILT)4 is an immunosuppressive molecule mainly expressed i...

    Authors: Qing Li, Juan Li, Shuyun Wang, Jingnan Wang, Xiaozheng Chen, Dongmei Zhou, Yuying Fang, Aiqin Gao and Yuping Sun
    Citation: Biomarker Research 2020 8:11
  20. Primary testicular lymphoma (PTL), often appearing as focal masses in the scrotum and epididymides, is the most frequent testicular tumor in aged men. Although MYD88 and CD79B mutations were the most common ge...

    Authors: Xinfeng Wang, Xiaoyu Xu, Wenzhi Cai, Haiyan Bao, Hongming Huang, Yifei Liu, Xi Yang, Changgeng Ruan, Depei Wu, Hongjie Shen and Suning Chen
    Citation: Biomarker Research 2020 8:10
  21. High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung...

    Authors: Yongfeng Wu, Jinming Xu, Jiawei Xu, Yiqing Wang, Luming Wang, Wang Lv and Jian Hu
    Citation: Biomarker Research 2020 8:9
  22. The prognosis of colorectal cancer (CRC) is still challenging to evaluate or predict. Recently, long non-coding RNAs (lncRNAs) have been found to play an important role in tumorigenesis and prognosis, however,...

    Authors: Rui Huang, Lian Zhou, Yue Chi, Haibo Wu and Lei Shi
    Citation: Biomarker Research 2020 8:8
  23. MiRNAs have been widely reported as the therapeutic target for hepatocellular carcinoma (HCC). However, mirna clusters, as the more impressive tumor regulatory factors, have received little attention. By deepl...

    Authors: Tao Rui, Siyi Xu, Shi Feng, Xueyou Zhang, Haitao Huang and Qi Ling
    Citation: Biomarker Research 2020 8:7
  24. Altered expression of T cell immune inhibitory receptors may result in immunosuppression and associate with the poor prognosis of leukemia patients in which the leukemic bone marrow (BM) microenvironment may c...

    Authors: Jiaxiong Tan, Zhi Yu, Jingying Huang, Youchun Chen, Shuxin Huang, Danlin Yao, Ling Xu, Yuhong Lu, Shaohua Chen and Yangqiu Li
    Citation: Biomarker Research 2020 8:6
  25. We used the Toponome Imaging System (TIS) to identify “patterns of marker expression”, referred to here as combinatorial molecular phenotypes (CMPs) in alveolar macrophages (AM) in response to the innate immun...

    Authors: David S. Phelps, Vernon M. Chinchilli, Judith Weisz, Debra Shearer, Xuesheng Zhang and Joanna Floros
    Citation: Biomarker Research 2020 8:5
  26. The MER signaling pathway represents an attractive therapeutic target for human cancers. Growth arrest–specific protein 6 (GAS6)–induced MER phosphorylation is often unstable and difficult to detect without pe...

    Authors: Yaoyu Chen, Margaret Favata, Michelle Pusey, Jun Li, Yvonne Lo, Min Ye, Richard Wynn, Xiaozhao Wang, Wenqing Yao and Yingnan Chen
    Citation: Biomarker Research 2020 8:4
  27. Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anch...

    Authors: Di Wu, Jiang Lv, Ruocong Zhao, Zhiping Wu, Diwei Zheng, Jingxuan Shi, Simiao Lin, Suna Wang, Qiting Wu, Youguo Long, Peng Li and Yao Yao
    Citation: Biomarker Research 2020 8:3
  28. Thalidomide, lenalidomide and pomalidomide are immunomodulatory drugs (IMiDs) effective in the treatment of multiple myeloma, myelodysplastic syndrome (MDS) with deletion of chromosome 5q and other hematologic...

    Authors: Shaobing Gao, Shichao Wang and Yongping Song
    Citation: Biomarker Research 2020 8:2
  29. Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural and outer layer of tissues surrounding the lungs. MPM is primarily caused by occupational exposure to asbestos ...

    Authors: Min-Kyu Kim, Hyun-won Kim, Mirae Jang, Sung Soo Oh, Suk-Joong Yong, Yangsik Jeong, Soon-Hee Jung and Jong-Whan Choi
    Citation: Biomarker Research 2020 8:1
  30. Immunotherapy is currently under investigation in B3 Thymoma (TB3) and Thymic Carcinoma (TC). PD-L1 expression has been evaluated on a limited number of patients with selected antibodies. We aimed to analyze c...

    Authors: Isabelle Rouquette, Estelle Taranchon-Clermont, Julia Gilhodes, Maria-Virginia Bluthgen, Romain Perallon, Lara Chalabreysse, Anne De Muret, Veronique Hofman, Alexander Marx, Marie Parrens, Veronique Secq, Vincent Thomas de Montpreville, Françoise Galateau-Salle, Pierre Brousset, Julie Milia, Nicolas Girard…
    Citation: Biomarker Research 2019 7:28
  31. Tamoxifen treatment has previously been reported to confer life-prolonging effects in patients with advanced pancreatic cancer, and most evidently so in women. None of these trials did however include biomarke...

    Authors: Gustav Andersson, Sebastian Lundgren, Margareta Heby, Björn Nodin, Jacob Elebro and Karin Jirström
    Citation: Biomarker Research 2019 7:26
  32. Tumor-associated antigens (TAA) or cancer biomarkers are major targets for cancer therapies. Antibody- based agents targeting the cancer biomarkers include monoclonal antibodies (MoAbs), radiolabeled MoAbs, bi...

    Authors: Delong Liu
    Citation: Biomarker Research 2019 7:25
  33. Phenotypic and functional heterogeneity is one of the hallmarks of human cancers. Tumor genotype variations among tumors within different patients are known as interpatient heterogeneity, and variability among...

    Authors: Mingzhou Guo, Yaojun Peng, Aiai Gao, Chen Du and James G. Herman
    Citation: Biomarker Research 2019 7:23
  34. The original article [1] contains an error in the legend of Fig. 1 whereby it is incorrectly stated that MEC stands for ‘mitoprostate cancer using magnetic resonance imagingxantrone, etoposide, cyclophosphamid...

    Authors: Juanjuan Zhao, Yongping Song and Delong Liu
    Citation: Biomarker Research 2019 7:21

    The original article was published in Biomarker Research 2019 7:19

  35. This study evaluated breast tissue stiffness measured by ultrasound elastography and the percent breast density measured by magnetic resonance imaging to understand their relationship.

    Authors: Jeon-Hor Chen, Siwa Chan, Yang Zhang, Shunshan Li, Ruey-Feng Chang and Min-Ying Su
    Citation: Biomarker Research 2019 7:20
  36. FMS-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) remains as one of the most frequently mutated genes in acute myeloid leukemia (AML), especially in those with normal cytogenetics. The FLT3-IT...

    Authors: Juanjuan Zhao, Yongping Song and Delong Liu
    Citation: Biomarker Research 2019 7:19

    The Correction to this article has been published in Biomarker Research 2019 7:21

  37. CAR-T cell therapy targeting CD19 has achieved remarkable success in the treatment of B cell malignancies, while various solid malignancies are still refractory for lack of suitable target. In recent years, a ...

    Authors: Jiang Lv and Peng Li
    Citation: Biomarker Research 2019 7:18
  38. The peroxiredoxins (PRDXs) gene family has been demonstrated to participate in carcinogenesis and development of numerous cancers and the prognostic values in several cancers have been evaluated already. Purpo...

    Authors: Jie Mei, Leiyu Hao, Xiaorui Liu, Guangshun Sun, Rui Xu, Huiyu Wang and Chaoying Liu
    Citation: Biomarker Research 2019 7:16
  39. The discovery of JAK2V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultim...

    Authors: Bing Li, Raajit K. Rampal and Zhijian Xiao
    Citation: Biomarker Research 2019 7:15
  40. The epidermal growth factor receptor (EGFR) monoclonal IgG1 antibody cetuximab is approved for first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen (plati...

    Authors: Madelyn Espinosa-Cotton, Elana J. Fertig, Laura P. Stabile, Autumn Gaither-Davis, Julie E. Bauman, Sandra Schmitz, Katherine N. Gibson-Corley, Yinwen Cheng, Isaac J. Jensen, Vladimir P. Badovinac, Douglas Laux and Andrean L. Simons
    Citation: Biomarker Research 2019 7:14

Annual Journal Metrics